Aavantgarde

Aavantgarde company information, Employees & Contact Information

Explore related pages

Related company profiles:

AAVantgarde is a clinical stage, biotechnology company advancing best-in-class therapies for patients with inherited retinal diseases (IRDs). With a strong foundation in translational science and a commitment to clinical excellence, AAVantgarde is working to bring transformative therapies to patients.

Company Details

Employees
55
Address
All Stargardt Patients Independently Of Their Abca4 Mutation: Https://lnkd.in/dyevcxkz
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Looking for a particular Aavantgarde employee's phone or email?

Aavantgarde Questions

News

AAVantgarde’s Stargardt Gene Therapy AAVB-039 Garners FDA Orphan Drug Designation, Cleared for Trial in UK - CGTLive®

AAVantgarde’s Stargardt Gene Therapy AAVB-039 Garners FDA Orphan Drug Designation, Cleared for Trial in UK CGTLive®

AAVantgarde’s AAVB-039 gene therapy to treat Stargardt disease receives orphan drug status from FDA - Ophthalmology Times

AAVantgarde’s AAVB-039 gene therapy to treat Stargardt disease receives orphan drug status from FDA Ophthalmology Times

AAVantgarde, Ocular Therapeutix, Oculis announce EURETINA presentations - Modern Retina

AAVantgarde, Ocular Therapeutix, Oculis announce EURETINA presentations Modern Retina

FDA Approves AAVantgarde’s IND Application for Stargardt Gene Therapy - BioPharm International

FDA Approves AAVantgarde’s IND Application for Stargardt Gene Therapy BioPharm International

AAVantgarde’s Stargardt Gene Therapy AAVB-039 Garners FDA Fast Track Designation - CGTLive®

AAVantgarde’s Stargardt Gene Therapy AAVB-039 Garners FDA Fast Track Designation CGTLive®

AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease - The Manila Times

AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease The Manila Times

AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial - Koreabizwire

AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial Koreabizwire

AAVantgarde Bio receives IND clearance for AAVB-039 - Ophthalmology Times

AAVantgarde Bio receives IND clearance for AAVB-039 Ophthalmology Times

AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies - Ophthalmology Times Europe

AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies Ophthalmology Times Europe

AAVantgarde Bio Doses First Patient in Trial for Usher Syndrome Gene Therapy AAVB-081 - CGTLive®

AAVantgarde Bio Doses First Patient in Trial for Usher Syndrome Gene Therapy AAVB-081 CGTLive®

Top Aavantgarde Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant